Angeles Wealth Management LLC Buys Shares of 1,526 Repligen Co. (NASDAQ:RGEN)

Angeles Wealth Management LLC bought a new position in shares of Repligen Co. (NASDAQ:RGEN) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 1,526 shares of the biotechnology company’s stock, valued at approximately $220,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. UMB Bank n.a. grew its holdings in Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares during the period. Blue Trust Inc. boosted its position in shares of Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares in the last quarter. Resources Management Corp CT ADV acquired a new position in shares of Repligen in the 3rd quarter valued at $37,000. Quarry LP increased its position in shares of Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 239 shares in the last quarter. Finally, nVerses Capital LLC acquired a new stake in Repligen during the 3rd quarter worth $45,000. 97.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Canaccord Genuity Group initiated coverage on shares of Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. TD Cowen began coverage on shares of Repligen in a research note on Monday. They issued a “buy” rating and a $200.00 price target on the stock. HC Wainwright dropped their price objective on shares of Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Finally, Wolfe Research assumed coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $186.00.

Repligen Stock Performance

RGEN opened at $153.86 on Tuesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The business’s 50-day simple moving average is $155.37 and its 200 day simple moving average is $148.93. The firm has a market capitalization of $8.62 billion, a PE ratio of -415.83, a PEG ratio of 4.54 and a beta of 0.99. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.23 EPS. As a group, sell-side analysts expect that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.